Table 2.
Logistic regression analysis of decreased tumour-infiltrating lymphocytes.
| Univariate | p value | Multivariate | p value | |||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age (≥65 vs. <65) | 0.74 | 0.25–2.21 | 0.59 | |||
| Tumour size (≥pT2 vs. <pT2) | 2.04 | 0.83–4.99 | 0.12 | |||
| Nodal status (positive vs. negative) | 2.36 | 0.97–5.75 | 0.06 | |||
| Subtype (TNBC vs. others) | 1.39 | 0.57–3.41 | 0.47 | |||
| HG (3 vs. 1–2) | 6.53 | 2.18–19.6 | 0.001 | 5.71 | 1.75–18.06 | 0.004 |
| RFI (≥median vs. <median) | 0.66 | 0.27–1.59 | 0.36 | |||
| Site of recurrence (distant vs. locoregional) | 0.97 | 0.38–2.52 | 0.96 | |||
| Adjuvant CT (yes vs. no) | 7.65 | 2.77–21.1 | <0.001 | 6.85 | 2.34-20.08 | <0.001 |
| Adjuvant RT (yes vs. no) | 1.54 | 0.64–3.73 | 0.34 | |||
| Adjuvant HT (yes vs. no) | 1.39 | 0.58–3.35 | 0.46 | |||
CT chemotherapy, CI confidence interval, HG histological grade, HT hormone therapy, RT radiotherapy, RFI recurrence-free interval, OR odds ratio, RT radiotherapy, RFI recurrence-free interval, OR odds ratio, TNBC triple-negative breast cancer, TIL tumour-infiltrating lymphocyte.